5 completed, 4 unknown, 2 terminated. 8 Phase 3, 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Terminated 2, Unknown 1 |
| Phase 2 | 4 | Terminated 2, Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
Follow Repurposed Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion DPI-386 Nasal Gel, Placebo - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 503 | 2022-08-23 | 2023-03-21 |
| Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance DPI-386 Nasal Gel, Placebo Nasal Gel - Motion Sickness, Space, Motion Sickness | Phase 2 | Unknown | Repurposed Therapeutics, Inc. | 30 | 2022-01-21 | 2024-05-17 |
| Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance DPI-386 Nasal Gel, Other (e.g., promethazine, meclizine) - Motion Sickness, Space, Motion Simulation | Phase 2 | Unknown | Repurposed Therapeutics, Inc. | 80 | 2021-08-10 | 2024-05-16 |
| Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion DPI-386 Nasal Gel, Placebo - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 140 | 2021-06-14 | 2021-09-17 |
| Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness DPI-386 Nasal Gel, Placebos - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 102 | 2019-06-09 | 2019-12-03 |
| Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects Scopolamine, Placebo Nasal Gel - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 98 | 2019-06-07 | 2023-05-06 |
| The Prevention and Treatment of Nausea Associated With Motion Sickness Scopolamine Nasal Gel, Placebo - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 300 | 2019-04-26 | 2019-12-03 |
| Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness scopolamine HBr, Transdermal Scopolamine - Motion Sickness | Phase 3 | Unknown | Repurposed Therapeutics, Inc. | 300 | 2019-04-22 | 2020-02-17 |
| Scopolamine in Healthy Volunteers Scopolamine - Major Depressive Disorder (MDD) | Phase 1 | Unknown | Repurposed Therapeutics, Inc. | 130 | 2018-08-01 | 2020-02-17 |
| DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness DPI-386 Nasal Gel, DPI-386 Placebo Nasal Gel, Transderm Scop® - Motion Sickness | Phase 2 / Phase 3 | Terminated | Repurposed Therapeutics, Inc. | 23 | 2018-06-29 | 2020-01-07 |
| Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray Scopolamine, Placebo - Motion Sickness | Phase 2 / Phase 3 | Terminated | Repurposed Therapeutics, Inc. | 63 | 2014-06-01 | 2018-01-17 |
Motion Sickness (9) · Space Motion Sickness (2) · Depressive Disorder, Major (1)
Scopolamine (9) · Meclizine (1) · Promethazine (1)
United States (11)
David Helton (4) · David R Helton (3) · Scott J Wood, PhD (2) · Dave Helton (1) · Willliam J Becker, Phd (1)